We use cookies to make your visit to our website as pleasant as possible. If you continue to use the website, you agree to our privacy policy and to the use of cookies. More information about cookies and how ImpediMed uses them is available here.
Accept Cookies
NAPBC STANDARDS
Meet Accreditation Standards with a Lymphedema Prevention Program
Learn More

Lymphedema Prevention Program

Together, We Can End Breast Cancer-Related Lymphedema.

View the Video
Request Demo
Lymphedema Prevention Program
CLINICAL PRACTICE GUIDELINES
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship

The NCCN Guidelines® are consistent about the importance of early detection of lymphedema and use of an objective tool, such as bioimpedance spectroscopy.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship V.1.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed March 24, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Learn More

Reduce the Burden of Breast Cancer-Related Lymphedema (BCRL) through Early Detection Using Bioimpedance Spectroscopy (BIS) and Intervention

Chronic BCRL Management Can be an Expensive, Complex, and Lifelong Issue for Patients

1 in 5 breast cancer patients will be impacted by lymphedema1

Patients suffering from BCRL often experience isolation, body dissatisfaction and depression2

Increased risk of wounds and infection with potential for hospitalization are common side effects3,4

Chronic BCRL Management Demands Significant Time and Financial Resources

Patients suffering from BCRL often experience a notable decline in their quality of life, and if their disease is left untreated, it can become a life-long condition.

Chronic BCRL Management Demands Significant Time and Financial ResourcesChronic BCRL Management Demands Significant Time and Financial Resources

It is Well Established that Breast Cancer-Related Lymphedema (BCRL) can be Resolved with Early Detection and Intervention

Lymphedema develops in stages, and a university of Kansas study found that when lymphedema is detected at stage 0 or stage 1 it is reversible, but in stages 2 and 3 it is not. These findings demonstrate how early conservative intervention and prospective monitoring with BIS can significantly lower rates of BCRL and persistent BCRL (pBCRL).5

It is Well Established that Breast Cancer Related Lymphedema (BCRL) can be Resolved with Early Detection and InterventionIt is Well Established that Breast Cancer Related Lymphedema (BCRL) can be Resolved with Early Detection and Intervention

Bioimpedance Spectroscopy (BIS) is the Most Effective Method for Lymphedema Detection at the Subclinical Stage

THE PREVENT TRIAL

PREVENT is the Largest Randomized Trial to Access Lymphedema Prevention

92% of patients with early detection using L-Dex and intervention did not progress to chronic lymphedema.6

Learn More About PREVENT
BREAST CANCER

L-Dex® is Designed for Lymphedema

L-Dex is 80% sensitive and 90% specific in detecting subclinical lymphedema with a 6.5 change from baseline, following surgery.7

Learn More About L-Dex

Discover the Benefits of a Lymphedema Prevention Program

Effective Care Coordination & Collaboration

Effective Care Coordination & Collaboration

Enhance survivorship and maximize patient health for breast cancer patients by adopting a unified approach to the treatment of breast cancer related lymphedema (BCRL).

Learn More
Patient Attraction & Satisfaction

Patient Attraction & Satisfaction

91% of patients surveyed believe cancer care teams should offer patients a Lymphedema Prevention Program.

Learn More
Effectively Meet Accreditation Standards for BCRL Care

Effectively Meet Accreditation Standards for BCRL Care

Successfully align with standards like the National Accreditation Program for Breast Centers (NAPBC) and the Commission on Cancer (COC), which both support lymphedema management throughout cancer treatment.

COC Standards
NAPBC Standards

Streamline Implementation by Leveraging the Expertise of ImpediMed’s Team

Evidence-Based Protocol for Optimal Patient Outcomes

Test

Test all patients at-risk of lymphedema using SOZO® with L-Dex

  • Baseline
  • Year 1-3: Every 3 months
  • Year 4-5: Every 6 months
  • Year 6+: Annually8

Trigger

L-Dex increase of 6.5 or more from baseline indicates a likelihood of subclinical lymphedema8

Treat

At-home treatment with compression garments

  • 4 weeks
  • 12 hours per day8

ImpediMed’s Clinical Team has Completed Numerous Successful Implementations Through Innovative Strategies, Multi-Disciplinary Collaboration, and Streamlined Technical Solutions


Innovative Strategies

  • Any care team can easily tailor the program workflow to better align with the unique needs of their practice and patients.
  • Our lymphedema prevention protocol invites a streamlined approach to patient monitoring and tracking for lymphedema progression.

Multi-Disciplinary Collaboration

  • The reimbursement support team is extremely knowledgeable and prepared to work alongside your practice to improve patient access to SOZO testing.
  • Our customer support team is equipped with access to valuable resources such as patient education, hospital marketing materials, and training.

Technical Solutions

  • ImpediMed’s system and software solutions meet the highest standard of industry and regulatory requirements.
  • The care team can easily access SOZO data directly from their EHR system in real-time.

SOZO® Digital Health Platform

With the SOZO Digital Health Platform and L-Dex, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphedema.

Discover SOZO

SOZO® Digital Health Platform with nurse and patient

REQUEST DEMO
Prevent Lymphedema with ImpediMed’s BIS

See how the SOZO Digital Health Platform works.

Request Demo
RESOURCES

Learn More About Coverage and Reimbursement for Lymphedema Testing Using SOZO

Reimbursement
RESOURCES

Review Comprehensive Education Materials and Past Webinars

Webinars & Events
RESOURCES

Discover the Strong Clinical Evidence Supporting Lymphedema Prevention Programs

Clinical Evidence

References

  1. Gillespie, T. C., Sayegh, H. E., Brunelle, C. L., Daniell, K. M., & Taghian, A. G. (2018). Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments. Gland Surgery, 7(4), 379–403. https://doi.org/10.21037/gs.2017.11.04
  2. Teo I, et al. Examining pain, body image, and depressive symptoms in patients with lymphedema secondary to breast cancer. Psychooncology. 2015 Nov;24(11):1377-83. Doi:10.1002/pon.3745. Epub 2015 Jan 20. PMID: 25601235.
  3. Shah C, et al. The impact of monitoring techniques on progression to chronic breast cancer‑related lymphedema: a meta‑analysis comparing bioimpedance spectroscopy versus circumferential measurements. Breast Cancer Research and Treatment 2020; https://doi.org/10.1007/s10549-020-05988-6.
  4. Dean LT, et al. “It still affects our economic situation.” A long-term economic burden of breast cancer and lymphedema. Supp Care Canc 2017; https://doi.org/10.1007/s00520-018-4418-4.
  5. Kilgore L, at al. Reducing breast cancer-related lymphedema (BCRL) through prospective surveillance monitoring using bioimpedance spectroscopy (BIS) and patient direction self-interventions. Ann Surg Oncol 2018;http://doi.org/10.1245/s10434-018-6601-8.
  6. Ridner SH, et al. A Randomized Clinical Trial of Bioimpedance Spectroscopy or Tape Measure Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention. Lymphatic Research & Biology 2022.
  7. Fu MR, et al. L-dex ratio in detecting breast cancer-related lymphedema: reliability, sensitivity, and specificity. (2013). L-dex ratio in detecting breast cancer-related lymphedema: reliability, sensitivity, and specificity. PubMed. https://pubmed.ncbi.nlm.nih.gov/24354107
  8. Shah, et al. Bioimpedance Spectroscopy for Breast Cancer Related Lymphedema Assessment: Clinical Practice Guidelines. Breast Cancer Research and Treatment 2022.